The Effect of Paternal Age on Relapse in First-Episode Schizophrenia by Chang, WC et al.
Title The Effect of Paternal Age on Relapse in First-EpisodeSchizophrenia
Author(s) Hui, CLM; Chiu, CPY; Li, YK; Law, CW; Chang, WC; Chan, KW;Lee, HME; Sham, PC; Chen, EYH
Citation Canadian Journal of Psychiatry, 2015, v. 60  n. 8, p. 346-353
Issued Date 2015
URL http://hdl.handle.net/10722/226402
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
www.LaRCP.ca346   W   La Revue canadienne de psychiatrie, vol 60, no 8, août 2015
CanJPsychiatry 2015;60(8):346–353
Key Words: paternal age, 
maternal age, relapse, 
predictors, first-episode 
schizophrenia
Received June 2014, revised, 
and accepted November 2014.
Original Research
The Effect of Paternal Age on Relapse in First-Episode 
Schizophrenia
Christy L M Hui, PhD1; Cindy P Y Chiu, MBBS2; Yuet-Keung Li, BSoc3; Chi-Wing Law, MBBS4; 
Wing-Chung Chang, MBChB5; Sherry K W Chan, MBBS5; Edwin H M Lee, MBChB6;  
Pak Sham, PhD7; Eric Y H Chen, MD7
1 Research Assistant Professor, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China.
2 Clinical Assistant Professor, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China.
3 Research Assistant, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China.
4 Associate Consultant, Department of Psychiatry, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
5 Clinical Assistant Professor, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China.
6 Clinical Assistant Professor, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China. 
Correspondence: Department of Psychiatry, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China; edwinlhm@hku.hk. 
7 Professor, Department of Psychiatry, University of Hong Kong, Hong Kong Special Administrative Region, China; Professor, State Key Laboratory of Brain 
and Cognitive Sciences, University of Hong Kong, Hong Kong Special Administrative Region, China.
Objective: Multiple etiological and prognostic factors have been implied in schizophrenia 
and its outcome. Advanced paternal age has been reported as a risk factor in 
schizophrenia. Whether this may affect schizophrenia outcome was not previously studied. 
We hypothesized that advanced paternal age may have a negative effect on the outcome of 
relapse in schizophrenia.
Method: We interviewed 191 patients with first-episode schizophrenia and their relatives 
for parental ages, sociodemographic factors at birth, birth rank, family history of psychotic 
disorders, and obstetric complications. The outcome measure was the presence of relapse 
at the end of the first year of treatment.
Results: In the 1-year follow-up period, 42 (22%) patients experienced 1 or more 
relapses. The mean paternal age was 34.62 years (SD 7.69). Patients who relapsed had 
significantly higher paternal age, poorer medication adherence, were female, and were 
hospitalized at onset, compared with patients who did not relapse. A multivariate regression 
analysis showed that advanced paternal age (OR 1.05, 95% CI 1.01 to 1.10), medication 
nonadherence (OR 2.37, 95% CI 1.12 to 4.99), and female sex (OR 2.44, 95% CI 1.14 
to 5.24) independently contributed to a higher risk of relapse. Analysis between different 
paternal age groups found a significantly higher relapse rate with paternal age over 40.
Conclusions: Advanced paternal age is found to be modestly but significantly related to 
more relapses, and such an effect is the strongest at a cut-off of paternal age of 40 years 
or older. The effect is less likely to be mediated through less effective parental supervision 
or nonadherence to medication. Other possible biological mechanisms need further 
explorations.
W W W
L’effet de l’âge paternel sur la rechute lors du premier épisode de 
schizophrénie
Objectif : De multiples facteurs étiologiques et pronostiques sont impliqués dans la 
schizophrénie et son issue. L’âge paternel avancé a été signalé comme étant un facteur de 
risque de la schizophrénie, mais il n’a pas été déterminé si ce facteur peut influer sur l’issue 
de la schizophrénie. Nous avons émis l’hypothèse que l’âge paternel avancé peut avoir un 
effet négatif sur l’issue d’une rechute de la schizophrénie. 
Méthode : Nous avons interviewé 191 patients au premier épisode de schizophrénie 
et leurs familles au sujet de l’âge des parents, des facteurs sociodémographiques à la 
naissance, du rang de naissance, des antécédents familiaux de troubles psychotiques, et 
des complications obstétriques. La mesure du résultat était la présence d’une rechute à la 
fin de la première année de traitement.
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Abbreviations
AP antipsychotic
DUP duration of untreated psychosis
EASY Early Assessment Service for Young people with  
 psychosis
FEP first-episode psychosis
IRAOS Interview for the Retrospective Assessment of the Onset 
 of Schizophrenia
OC obstetric complication
PANSS Positive and Negative Syndrome Scale
SUD substance use disorder
Clinical Implications
• Advanced paternal age (particularly 40 years and older) 
has a negative effect on relapse following FEP, even 
after controlling for medication discontinuation and sex.
• Our findings raise an interesting research question of 
how advanced paternal age might contribute to possible 
biological and psychosocial mechanisms leading to 
relapse.
Limitations
• The exact timing of relapse was not measured.
• The relatively short follow-up period also limited the 
observation. Hence observation may only allow for 
distinction between a minority of the patients with more 
serious illness and those running a more benign course.
• The potential confounding variable of premorbid 
adjustment, caregivers’ negative comments, and 
substance abuse were not measured.
The outcome of schizophrenia is subject to the influence of factors ranging from biological to psychosocial 
aspects.1–3 After clinical stabilization, where positive 
psychotic symptoms are expected to have largely subsided, 
other aspects of the illness, such as relapse, become 
increasingly pertinent in the course of recovery.4–7 The 
re-emergence of psychotic symptoms is distressing to the 
patients and their families,8 and some relapses may even 
lead to treatment resistance.9 In a recent meta-analytic 
review on 109 relapse predictors, Álvarez-Jiménez et al10 
identified medication discontinuation, persistent SUD, 
caregivers’ critical comments, and premorbid adjustment to 
be significant. Further evidence within the early intervention 
services in different countries has also confirmed these 
findings.11–13 The continual identification of predictors for 
relapse, especially in the early phase of the disorder, is 
therefore the logical next step in research.10,14
Studying etiological factors not only helps us to understand 
the illness but also suggests ways to find potential subgroups 
of the disorder that may affect clinical management.15–17 
Advanced paternal age has been reported as a risk factor in 
disease development in several birth and army cohorts,18–22 
and as a predisposing factor for a particular subtype of 
schizophrenia.23–26 Interestingly, a recent meta-analysis has 
reported both older (30 years or older) and younger (younger 
than 25 years) fathers increased the risk of schizophrenia; 
and, in particular, younger paternal age effect was found 
among male but not female offspring, indicating the 
potential confounding effect of sex.27
At present, many studies focus on paternal age as an 
etiological factor of schizophrenia. Whether paternal age 
has any effect on the clinical course of illness (for example, 
relapse) in schizophrenia has not been explored. Evidence 
has begun to suggest that patients with advanced paternal 
age have more severe psychotic symptoms after medication 
withdrawal.26 The preliminary data call for a need to 
further examine the neurobiological factors, symptoms, 
treatment effects, and course of illness in patients with older 
fathers, which may lead to a meaningful differentiation 
between subtypes of the disorder.26 Therefore, we 
consider paternal age to be a probable prognostic indicator 
adversely influencing the outcome of psychotic relapse in 
schizophrenia.
Examining the role of advanced paternal age in early 
relapse within 12 months from the start of treatment is 
important because this is the time when most patients would 
have remitted from the first episode and embarked on a 
rehabilitation program or resumed work and (or) study. We 
Résultats : Sur une période de suivi d’un an, 42 patients (22 %) ont connu 1 ou plusieurs 
rechutes. L’âge paternel moyen était de 34,62 ans (ET 7,69). Les patients qui rechutaient 
avaient un âge paternel significativement plus élevé, une mauvaise observance des 
médicaments, étaient de sexe féminin, et étaient hospitalisés au début de la maladie, 
comparativement aux patients qui ne rechutaient pas. Une analyse de régression multivariée 
a montré que l’âge paternel avancé (RC 1,05; IC à 95 % 1,01 à 1,10), la non-observance des 
médicaments (RC 2,37; IC à 95 % 1,12 à 4,99) et le sexe féminin (RC 2,44; IC à 95 % 1,14 
à 5,24) contribuaient indépendamment à un risque de rechute plus élevé. L’analyse entre les 
différents groupes d’âge paternel a révélé un taux de rechute significativement plus élevé 
lorsque l’âge paternel dépassait 40 ans.
Conclusions : L’âge paternel avancé est relié modestement mais significativement à plus de 
rechutes, et cet effet est le plus marqué au seuil de l’âge paternel supérieur à 40 ans ou plus. 
Cet effet est moins probablement produit par une supervision parentale moins efficace ou la 
non-observance des médicaments. D’autres mécanismes biologiques possibles doivent être 
explorés. 
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therefore hypothesized that patients with older fathers have 
more relapses at 1-year follow-up. We speculated that any 
identified effect of paternal age in relapse to be unrelated to 
medication adherence and sex, and that the main hypothesis 




Subjects were recruited consecutively as they presented to 
the EASY clinics for follow-up at Queen Mary Hospital 
and Pamela Youde Nethersole Eastern Hospital. EASY is 
a specialized early intervention service for FEP patients 
aged younger than 26 years old.28 Patients came from a 
catchment area within Hong Kong serving a population 
of 1.3 million. Intervention consisted of the use of low-
dose APs, comprehensive outpatient and community-
based care, and designated case workers working with a 
standardized psychoeducation program.28 Subjects were 
eligible for our study if they were suffering from first-
episode schizophrenia at initial presentation to the service 
and fulfilled the Diagnostic and Statistical Manual of 
Mental Disorders criteria29 for schizophrenia on review by 
the end of the first year of treatment. Patients with a history 
of special school attendance; physical conditions, such as 
brain damage, delusional disorders, and substance-related 
psychotic disorders; or those with known SUD during 
the first year of treatment were excluded. Patients with 
significant comorbid SUD or substance-related psychotic 
disorders were excluded, as the rate of substance abuse 
among remitted FEP patients in Hong Kong is relatively 
low. The study was approved by the institutional review 
boards at each site and all participants provided written 
informed consent.
Assessments
Basic demographic information, including sex, age at study 
entry, and age at onset, was collected. In evaluation of 
occupational functioning, the exact nature of occupation was 
asked (for example, primary school teacher, account clerk, 
or cleaner) and categorized into professional, high-skilled, 
skilled, and unskilled work, student, and unemployed.
Relapse was defined by a significant deterioration in 
positive symptoms (delusions, hallucination, and thought 
disorder) that led to a change in medication treatment or 
hospitalization.30 Admissions for other reasons, such as 
depressive episodes or suicidal attempts, were not counted as 
relapse if there were no deterioration in positive symptoms. 
Information was obtained from the subject’s clinical case 
notes and confirmed through interview with the patient and 
informant. Medication adherence was estimated to be good 
for being adherent in more than 50% of the time in the first 
month of AP treatment, and poor if otherwise, according to 
the self-report from patients’ and clinicians’ judgment.
DUP was determined according to the IRAOS.31 Subjects 
were assessed by trained clinicians for symptoms by the 
PANSS32 at initial presentation. Interrater reliability for 
PANSS positive subscale, negative subscale, total score, 
and DUP were performed on an independent sample of 12 
patients. The intraclass correlation was 0.87 for the PANSS 
positive subscale, 0.66 for the PANSS negative subscale, 
0.76 for the PANSS total score, and 0.99 for DUP. Other 
information, such as diagnosis and whether hospitalized at 
onset, were also obtained.
Subjects underwent a structured interview for parental 
sociodemographic details at birth. An informant (whenever 
possible, the subject’s mother), was interviewed for 
collateral information with the subject’s consent. The 
clinical case notes were also studied as an additional source 
of information. Paternal and maternal age (at time of 
subject’s birth) was obtained by directly asking the subject. 
Important dates, such as the world wars, were also used as 
reference points. Paternal and maternal occupation, and 
levels and years of education (excluding kindergarten) were 
also collected. The structured interview also recorded other 
details around the time of the subjects’ birth, such as type 
of accommodation (private housing, public housing, rented 
housing, boat, squatter hut, or village housing).
Assessment for family history was locally adapted based on 
the IRAOS, as many family members may not be aware of 
the diagnosis of a proband. The patient and informant were 
asked to describe each first- and second-degree relative in 
detail for the interviewer, specifically for any knowledge 
of mood, mental, or stress-related states, and behavioural 
abnormalities of that person. Only people with descriptions 
indicative of a psychotic disorder were included. For 
example, an uncle described as saying he was being 
persecuted and hearing voices of aliens would be included. 
A grandmother scolding others, sleeping poorly, appearing 
irritable with psychiatric follow-up would not be included 
without further relevant description. In ambiguous cases, an 
exclusive approach was adopted to preserve specificity and 
to avoid false positives.
The Obstetric Complications Scale,33 which has acceptable 
reliability by maternal recall,34 was used for OCs. For 
specificity purposes only, definite rather than equivocal 
OCs were counted. Precipitous labour was disregarded34,35 
as it systematically occurs in multiparous births without any 
definite complications. Birth rank within the same biological 
parents was recorded along with total sibship size.
Statistical Analysis
Data were analyzed using IBM SPSS Statistics 20.0 (IBM 
SPSS Inc, Armonk, NY). Descriptive statistics on sample 
characteristics and paternal and maternal data were reported. 
To test the primary hypothesis of whether advanced paternal 
age has an effect on relapse at 1 year, we first compared 
the potential variables (paternal and maternal age, sex, 
medication adherence, hospitalization, DUP, family history, 
OCs, birth rank, and sibship size) between people who 
relapsed and those who did not by independent t tests or 
chi-square tests. Those significant variables, with P values 
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of 0.05 or lower, were entered into a multivariate binary 
logistic regression to test for its independent predictive 
ability with relapse.
Results
Demographic and Clinical Data
Table 1 shows the characteristics of participants. Among 
the 194 eligible patients approached, 191 of them gave 
informed consent and were recruited into the study during 
a 4-month period. The sex ratio of the whole population 
was 94 males to 97 females, with a significantly higher 
proportion of males who did not relapse (54.4%) than those 
who did relapse (31.0%, P = 0.007). As expected, more 
patients who relapsed were hospitalized (66.7%) than those 
who did not relapse (49.0%, P = 0.04). Both groups did 
not differ in age at study entry, age at onset, occupational 
status, DUP, and positive and negative symptom scores 
at baseline. In general, the population had a mean age of 
23.43 years (range 13 to 58, SD 7.86) and the average onset 
age of psychotic disorders was 22.56 years (range 13 to 
56, SD 7.45). There were 76 (39.8%) patients who were 
unemployed and 66 (34.6%) patients who were students. 
Most of them had good medication adherence (n = 128, 
67.0%). The median DUP was 150 days (interquartile 
range 45 to 360). All participants were diagnosed with 
schizophrenia.
Paternal and Maternal Data
As shown in Table 2, the mean paternal age was 34.62 years 
(range 17 to 62, SD 7.69), and the predominant paternal 
occupation was unskilled worker (n = 91, 47.6%). For 
participants’ mothers, the mean maternal age was 28.52 
years (range 16 to 45, SD 5.53), and most of them were 
housewives (n = 90, 47.1%) or unskilled workers (n = 65, 
34%). Parental education was relatively low, with a mean 
of 7.32 years (SD 4.40) for fathers and 5.90 (SD 4.26) for 
mothers. One-fifth of the participants had a positive family 
history of psychotic disorders (n = 37, 19.4%). Around the 
time of the participants’ birth, 34% of them lived in private 
housing.
Predicting Relapse in 1 Year
At 1-year follow-up following first-episode schizophrenia, 
42 participants (22.0%) experienced 1 or more relapses, 
and 149 of them had no relapses (78.0%). Comparisons 
between people who did relapse and those who did not 
relapse found that higher paternal age (37.67, compared 
with 33.76, t = 2.778, df = 60, P = 0.007), poor medication 
adherence (47.6%, compared with 28.9%, χ2 = 5.217, 




Person who has 
not relapsed  
n = 149
Person who has 
relapsed  
n = 42 Tests
Sex, n (%) χ2 = 7.184, df = 1, P = 0.007
Female  97 (50.8)  68 (45.6)  29 (69.0)
Male 94 (49.2) 81 (54.4) 13 (31.0)
Age at study entry, years, mean (SD) 23.43 (7.86) 23.60 (8.14) 22.81 (6.84) ns
Age at onset, years, mean (SD) 22.56 (7.45) 22.79 (8.00) 21.76 (5.00) ns
Occupation status, n (%)
Unemployed 76 (39.8) 61 (40.9) 15 (35.7) ns
Students 66 (34.6) 50 (33.6) 16 (38.1) ns
Unskilled workers 16 (8.4) 14 (9.4) 2 (4.8) ns
Skilled workers 26 (13.6) 20 (13.4) 6 (14.3) ns
High-skilled workers 7 (3.7) 4 (2.7) 3 (7.1) ns
Professional workers 0 (0.0) 0 (0.0) 0 (0.0)
DUP, days, median (IQR) 150 (45–360) 150 (45–360) 105 (30–278) ns
Medication compliance, n (%) χ2 = 5.217, df = 1, P = 0.02
Poor 63 (33.0) 43 (28.9) 20 (47.6)
Good 128 (67.0) 106 (71.1) 22 (52.4)
Hospitalization at onset, n (%) 101 (52.9) 73 (49.0) 28 (66.7) χ2 = 4.107, df = 1, P = 0.04
PANSS, mean (SD)
Total score 81.07 (21.94) 82.06 (21.67) 77.23 (22.94) ns
Positive symptoms 21.40 (5.67) 21.44 (5.47) 21.23 (6.49) ns
Negative symptoms 16.49 (7.73) 16.63 (7.75) 15.93 (7.73) ns
General psychopathology 38.28 (11.23) 39.03 (11.27) 35.37 (10.78) ns
DUP = duration of untreated psychosis; ns = not significant; PANSS = positive and negative syndrome scale
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Person who has 
not relapsed  
n = 149
Person who has 
relapsed  
n = 42 Tests
Paternal age, years, mean (SD) 34.62 (7.69) 33.76 (7.33) 37.67 (8.25) t = 2.778, df = 60, P = 0.007
Paternal occupation, n (%) ns
Unemployed 0 (0.0) 0 (0.0) 0 (0.0) 
Students 1 (0.5) 1 (0.7) 0 (0.0) 
Unskilled workers 91 (47.6) 72 (48.3) 19 (45.2)
Skilled workers 58 (30.4) 47 (31.5) 11 (26.2)
High-skilled workers 29 (15.2) 22 (14.8) 7 (16.7)
Professional workers 12 (6.3) 7 (4.7) 5 (11.9)
Paternal education, years, mean (SD) 7.32 (4.40) 7.20 (4.38) 7.74 (4.49) ns
Paternal education level, n (%) ns
No formal education 21 (11.0) 18 (12.1) 3 (7.1)
Primary 73 (38.2) 56 (37.6) 17 (40.5)
Secondary 73 (38.2) 59 (39.6) 14 (33.3)
Matriculation or above 24 (12.6) 16 (10.7) 8 (19.0)
Maternal age, years, mean (SD) 28.52 (5.53) 28.15 (5.41) 29.86 (5.84) ns
Maternal occupation, n (%) ns
Unemployed 1 (0.5) 1 (0.7) 0 (0.0)
Students 1 (0.5) 1 (0.7) 0 (0.0)
Housewife 90 (47.1) 71 (47.7) 19 (45.2)
Unskilled workers 65 (34) 48 (32.2) 17 (40.5)
Skilled workers 20 (10.5) 18 (12.1) 2 (4.8)
High-skilled workers 11 (5.8) 7 (4.7) 4 (9.5)
Professional workers 3 (1.6) 3 (2.0) 0 (0.0)
Maternal education, years, mean (SD) 5.90 (4.26) 5.85 (4.24) 6.10 (4.40) ns
Maternal education level, n (%) ns
No education 42 (22.0) 35 (23.5) 7 (16.7)
Primary 73 (38.2) 54 (36.2) 19 (45.2)
Secondary 64 (33.5) 54 (36.2) 10 (23.8)
Matriculation or above 12 (6.3) 6 (4.0) 6 (14.3)
Accommodation, n (%) ns
Private 65 (34.0) 44 (29.5) 21 (50.0)
Others: public, rental, squatter, boat 126 (66.0) 105 (70.5) 21 (50.0)
Positive family history of psychotic 
disorders, n (%)
37 (19.4) 30 (20.1) 7 (16.7) ns
Definite obstetric complications, n (%) 29 (15.2) 25 (16.8) 4 (9.5) ns
Sibship size, mean (SD) 2.86 (1.56) 2.90 (1.53) 2.74 (1.68) ns
Birth rank, mean (SD) 2.07 (1.38) 2.03 (1.30) 2.21 (1.65) ns
ns = not significant
Table 3  Paternal age groups and relapse at 1 year
Outcome
<30 years  
n = 51
30 to 39 years 
n = 97
≥40 years 
n = 43 Total
Not relapsed at 1 year, n (%) 44 (86.3) 80 (82.5) 25 (58.1) 149 (78.0)
Relapsed at 1 year, n (%) 7 (13.7) 17 (17.5) 18 (41.9) 42 (22.0)
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df = 1, P = 0.02), female sex (69.0%, compared with 45.6%, 
χ2 = 7.184, df = 1, P = 0.007), and hospitalization at onset 
(66.7%, compared with 49.0%, χ2 = 4.107, df = 1, P = 
0.04) were significantly associated with relapse. However, 
maternal age was not significantly different between the 2 
groups (29.86, compared with 28.15, t = 1.778, df = 189, 
P = 0.07). Other nonsignificant relapse predictors were 
family history, OCs, birth rank, sibship size, and DUP.
A logistic regression was then performed to study the 
independent predictive abilities of these identified 
factors (paternal age, medication adherence, sex, and 
hospitalization at onset) with relapse. In this multivariate 
analysis, significant predictors for relapse included higher 
paternal age (β = 1.05, 95% CI 1.006 to 1.103, P = 0.03), 
poor adherence (β = 2.37, 95% CI 1.122 to 4.989, P = 0.02), 
and female sex (β = 2.44, 95% CI 1.136 to 5.235, P = 0.02). 
The full model (χ2 = 21.269, df = 4, P < 0.001) accounted 
for 10.5% to 16.2% of variance in relapse status, with 
79.1% of the prediction correct.
To further elucidate whether a particular paternal age range 
was significantly associated with relapse, patients were 
divided into 3 groups depending on paternal age: younger 
than 30 years, between 30 and 39 years, and 40 years and 
older. We found a significant effect of advanced paternal 
age on 1-year relapse rate (χ2 = 13.055, df = 2, P = 0.001) 
(Table 3). Post hoc chi-square tests revealed that the oldest 
age group (40 years and older) was significantly different 
from the middle group (30 to 39 years) (41.9%, compared 
with 17.5%, χ2 = 9.409, df = 1, P = 0.002) and the lowest 
age group (younger than 30 years) (41.9%, compared with 
13.7%, χ2 = 9.460, df = 1, P = 0.002). No difference was 
found between the lowest and the middle paternal age 
groups (13.7%, compared with 17.5%; χ2 = 0.355, df = 1, 
P = 0.55). A cut-off of paternal age of 40 years and older 
was related to more relapse.
Discussion
To our knowledge, there is no report of the effect of 
advanced paternal age on relapse at 1-year following the 
first episode of schizophrenia. Key findings were as follows: 
advanced paternal age modestly but significantly increased 
the risks of relapse; such an effect was independent of 
medication adherence, sex, maternal age, family history, 
OCs, birth rank, sibship size, and DUP; and such an effect 
was the strongest at a cut-off of paternal age of 40 years 
and older. Another finding was that the 1-year relapse rate 
in this sample was 22%. The result is comparable with a 
previous naturalistic study of first-episode schizophrenia in 
Hong Kong, where a relapse rate of 19% was found in the 
first year.36
To account for the paternal age effect on relapse, current 
knowledge on the biological and psychosocial hypotheses 
in explaining the development of schizophrenia has 
been put forward. The first of these postulations is that 
biological factors associated with high paternal age, for 
example, de novo mutation in spermatogenesis, may lead to 
developmental brain changes associated with an increased 
intrinsic biological propensity to relapse. Similar to the 
population-based cohort study in Sweden,22 our research 
indicated that people who did not relapse and those who did 
relapse did not differ in terms of family history of psychotic 
disorder. With the influence of familial vulnerability being 
equal in the 2 groups, advanced paternal age effect is clearly 
demonstrated among people who did relapse, suggesting 
that de novo mutation in spermatogenesis in older fathers, 
especially for those 40 years and older, may contribute to 
higher risk of relapse.
The second postulated psychosocial hypothesis is that 
older parents may be less effective in supervision of the 
patient’s adherence behaviour. If parental supervision is a 
key factor, we would expect a significant relation between 
maternal age and relapse as well. As the mother is often 
the key caregiver for patients with psychotic disorders,37,38 
we would expect that the relation between maternal 
age and relapse to be stronger than that for paternal age. 
The absence of such a relation in our data made this 
postulation unlikely. Likewise, we found that the relation 
between paternal age and relapse was not mediated by 
adherence behaviours, that is, paternal age and adherence 
each contribute independently to relapse. We explored if 
higher paternal or maternal age were related to adherence, 
however, no significant associations were found (P = 0.22 
and P = 0.74, respectively). Our data contrasted with the 
second hypothesis of low parental supervision on patients’ 
adherence behaviours leading to relapse. 
In hindsight, older Chinese fathers who are usually strict 
and heavily involved in the discipline of their children 
might lead them to express a higher level of critical 
comments toward their ill children. As caregivers’ critical 
comments were one of the more consistent relapse factors,10 
it is probable that critical comments is a mediating variable 
through which it expresses its impact on relapse. As this 
variable is not investigated in our study, whether the relation 
between advanced paternal age and relapse is mediated 
by more negative comments should be explored in future 
studies.
Our findings give further evidence to the hypothesis that 
a higher paternal age-related schizophrenia may represent 
a specific illness subtype. It has been suggested that 
patients born to older fathers had better treatment response 
in positive symptoms, irrespective of the treatment or 
the placebo groups.26,39 Although generalization may be 
an issue, as the sample was recruited from clinical trials 
and in patients with very early onset schizophrenia,39 
this and our findings also hint at the important influence 
of advanced paternal age on different course parameters 
in schizophrenia. Further investigations are needed 
to examine whether either one or both biological and 
psychosocial hypotheses play a role in moderating the 
relation between advanced paternal age and relapse, as well 
as whether these relations are specific to early or late-onset 
schizophrenia. Another significant finding is that females 
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were associated with more relapses than males. The result 
contradicts previous findings where male sex had poorer 
outcomes in general and more relapses.40,41 A potential 
explanation is that our female patients had a higher severity 
level of positive symptoms at onset (P = 0.04) than their 
male counterparts. Studies demonstrated that more severe 
positive symptoms at onset is predictive of relapse in recent 
onset psychosis.42 Moreover, we found a doubled relapse 
risk among patients with poor medication adherence. The 
link between nonadherence and relapse in first-episode 
schizophrenia has been reported consistently, both in 
naturalistic36,43 and in controlled studies.30,44–46 Despite this 
well-replicated finding, current interventions to enhance 
adherence in recent-onset psychosis remain a challenge, as 
nonadherence is not caused by one but a multiple of factors; 
and no single intervention can be effective for all patients.14 
Therefore, the exploration of predictors of relapse, other 
than nonadherence, would be important in designing new 
interventions to enhance medication adherence and reduce 
relapse.
Limitations
There are several limitations in our study. Some potential 
relapse predictors, such as persistent substance abuse, 
caregivers’ critical comments, and premorbid adjustment, 
were not measured. Although substance abuse may be 
relevant, its prevalence is relatively low in the Hong 
Kong population (5.5% for female and 9.3% for male in 
a comparable age group of 18- to 24-year-olds).47 Here, 
patients with significant comorbid SUD in the past year or 
substance-related psychotic disorders were excluded, and 
thus alcohol and substance abuse were not investigated as 
potential predictor. Additionally, measuring the variable of 
critical comments may require lengthy interviews using the 
Camberwell Family Interview with family members of the 
psychiatric patient, and thus were not investigated in our 
study. Likewise, premorbid adjustment was not measured. 
However, this made the exploration of its potential role in 
mediating the existing finding on advanced paternal age 
and relapse impossible. The exact timing of relapse was not 
measured. We acknowledge that reliable measurement of 
medication adherence is a difficult empirical challenge, and 
the way it measures compliance in our study may not be 
stringent enough to fully elucidate the effect of medication 
compliance on relapse.48–50 Further, the identification 
of relapse is now based on clinical judgment rather than 
measurement of symptoms, which might also weaken the 
strength of current findings. The relatively short follow-up 
period also limited the observation. Hence observation may 
only allow for distinction between a minority of the patients 
with more serious illness and those running a more benign 
course.
Clinical and Research Implications
Our study has furthered our understanding toward the role 
of paternal age in predicting psychotic relapse in first-
episode schizophrenia. The finding that patients with higher 
paternal age (particularly at 40 years and older) had more 
relapses is of great clinical and research significance. The 
effect of advanced paternal age still holds after controlling 
for medication discontinuation and sex. These data need 
to be replicated, perhaps with a longer follow-up period. 
The finding raises interesting research questions about 
how advanced paternal age might contribute to possible 
biological and psychosocial mechanisms leading to relapse. 
Future studies should confirm whether advanced paternal 
age may affect the initial response to treatment in patients 
with psychosis and represent a subtype of schizophrenia by a 
wider investigation into the neurobiology, psychopathology, 
treatment effects, and course of illness in patients.
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